Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

ObjectiveThe myosin-binding protein C (MYBPC3) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland. This cross-sectional observational study explored the penetrance and phenotypic burden among carriers of this single, prevalent found...

Full description

Bibliographic Details
Main Authors: Javier Diez, Begoña López, Barry J Maron, Berglind Adalsteinsdottir, Michael Burke, Ragnar Danielsen, Petr Jarolim, Jonathan Seidman, Christine E. Seidman, Carolyn Y Ho, Gunnar Th Gunnarsson
Format: Article
Language:English
Published: BMJ Publishing Group 2020-06-01
Series:Open Heart
Online Access:https://openheart.bmj.com/content/7/1/e001220.full

Internet

https://openheart.bmj.com/content/7/1/e001220.full

Similar Items